Edwards Lifesciences’ Sapien 3 artificial heart valve, implanted through a catheter, is an alternative for heart disease patients whose conditions are bad enough to make surgery too risky. Over the past two years it’s been FDA approved for an increasing number of procedure types, including for repairing existing artificial valves that are breaking down. The company’s growing footprint globally has driven strong sales abroad, where these kinds of minimally invasive heart procedures are becoming more popular. Edwards has been able to maintain at least a 24% net profit margin through the first half of 2017.
Looking for leads, investment insights, or competitive intelligence?
News about Edwards Lifesciences
A number of other health care execs earned high marks, too.